SCHEMBL15564286

SCHEMBL15564286

OCc1c(Cl)n(Cc2ccccc2)c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.59
P2RX4 Q99571 1/20 0.53
FOLH1 Q04609 2/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
TDP1 Q9NUW8 1/20 0.48
MAPK1 P28482 2/20 0.48
PLA2G2A P14555 2/20 0.47
GFER P55789 1/20 0.47
LMNA P02545 1/20 0.44
PGR P06401 1/20 0.44
SRC P12931 1/20 0.44
HSPD1 P10809 1/20 0.43
HSPE1 P61604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10493548 0.78 CYP19A1 (0.53) CYP19A1P2RX4FOLH1SMN1; SMN2KDM4E
SCHEMBL30007452 0.76 CYP19A1 (1.00) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1
SCHEMBL151053 0.76 CYP19A1 (1.00) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1
SCHEMBL9236147 0.75 CCR2 (0.59) CYP19A1P2RX4FOLH1SMN1; SMN2KDM4E
SCHEMBL4881610 0.74 FOLH1 (0.55) CYP19A1P2RX4FOLH1SMN1; SMN2KDM4E
SCHEMBL9398256 0.74 CYP19A1 (0.95) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1
Bromide SCHEMBL28888744 0.74 CYP19A1 (0.95) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1
Ammonia Solution, Strong SCHEMBL29210102 0.74 CYP19A1 (0.95) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1
SCHEMBL8506509 0.73 SMN1; SMN2 (0.58) CYP19A1P2RX4FOLH1SMN1; SMN2KDM4E
SCHEMBL5795385 0.72 CYP19A1 (0.68) CYP19A1P2RX4SMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
EP-2882725-A1 SUBSTITUTED HETERO-AZEPINONES F. Hoffmann-La Roche AG (CH) 2015-06-17 EP disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 CYP19A1 161/4885P2RX4 941/4885FOLH1 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.